Key Takeaways
- Volume-led growth despite price collapse: Revenue grew 13% YoY in Q4 on 15% volume growth, even as product realizations fell from peak to trough over the year. The derivatives and specialty segment doubled its revenue share to 38%, confirming the portfolio shift is underway.
- New capacities are ramping, not yet earning: CPVC resin, epichlorohydrin, and additional caustic soda were commissioned in FY23 but contributed only marginally. Their ramp, plus the chlorotoluene project on track for Q4 FY24, forms the FY24-25 growth thesis.
- Margins compressed by inventory and depreciation: EBITDA and PAT declined YoY as high-cost inventory flowed through and depreciation rose on newly commissioned assets. Management expects blended EBITDA margins to stabilize at 28% plus/minus 2% going forward.
- Balance sheet strengthened despite the capex cycle: Net debt fell by INR112 crores, net debt-to-EBITDA improved to 1.3x from 1.9x, and ROCE rose to 32%. Preference shares of INR62 crores were redeemed.
- What to watch next quarter: Whether ECH utilization climbs materially from 40%, whether CPVC prices find a floor, and whether the promised 50% derivative revenue share by FY24 year-end stays on track.
Volume Growth & the Realization Reset
- The top-line paradox: FY23 revenue grew 41% to INR2,196 crores despite realizations for all products starting at peak and ending at trough. Volume, not price, carried the year.
- Q4 volume engine: 15% YoY volume growth came from newly commissioned ECH and CPVC, plus partial contribution from existing products. Revenue reached INR562 crores, up 13% YoY.
- Caustic soda pricing stabilized: Q4 realization was around INR38,000 per ECU, which management called a realistic level in line with energy prices and subdued global demand. The price has kind of stabilized and may stay at this level or go up down the line.
- Chlorine drag: Chlorine remained a bit negative in the quarter, with in-house consumption at 65%. The target is 85% in two to three years, stepping to 75% once CPVC resin and chlorotoluene plants are commissioned.
- Inventory build is structural, not a warning: Inventory rose from INR154 crores to INR211 crores, driven by new ECH and CPVC stock that did not exist in FY22, bulk ECH exports in transit at year-end, and higher spares for expanded operations.
Maulik Patel: "FY '23 has been an exciting year even after a lot of volatility for the business. The realizations for all the products were at peak at the starting of the year and have reached to a bottom level by the end of the year. Even after this, our top line for the year as a whole has increased by 41% to INR2,196 crores."
Derivatives Ramp: ECH, CPVC & the Portfolio Shift
- Derivatives doubled their revenue share: The derivatives and specialty chemical segment contributed 38% of Q4 revenue, up from 19% a year ago. Management expects this to reach 50% by the end of the current financial year (FY24).
- ECH utilization climbing from a low base: Capacity utilization reached 40% in Q4, up from negligible levels in Q3. Export infrastructure is now in place in Houston and Antwerp, with the first vessel to Europe nearly arrived and the first to the US sailing shortly. Volume is expected to increase quarter-on-quarter from Q1 FY24.
- ECH demand tailwinds: China reopening and renewable energy demand are picking up, with the windmill market, a major epoxy resin consumer, opening up very fast. Export contracts with European and US customers are under discussion.
- CPVC at 90% utilization, expansion underway: Having nearly reached full capacity, CPVC is being expanded from 30,000 to approximately 45,000 tons per annum. India is a net importer and demand is growing, so absorption of the expanded capacity is expected to be easy.
- CPVC pricing has a little further to fall: Prices may decline another 5-10% from current levels, tracking PVC prices downward, but no drastic change is expected because Indian demand is also increasing.
- ECH and CPVC margin profile: On a normal basis, EBITDA margins of 25% to 30% are achievable, with a target ROCE of 25% or above. Raw material costs are eventually pass-through because demand for both products is good, though inventory lags can affect a quarter or two.
Milind Kotecha: "So if you track both the things put together, then you will see the margin has remained intact. But again, we would definitely not buy on spot and sell on spot. So again, the raw material that we have in our hand, with that lag only, there will be an impact on a margin for that particular quarter or maybe six months, till the time inventory I have. Otherwise, on a normal basis, one can, I mean, in this particular range, 25% to 30% margin is achievable."
Chlorotoluene: The Next Growth Leg
- First-mover project in India: Construction is 60-70% complete, with Phase 1 commissioning targeted for Q4 FY24. The project covers 15 products across 4-5 chemistries, starting with ring chlorination then side chain. Currently, everything is imported.
- Phase 1 financial ambition: Targeting more than INR300 crores turnover with a minimum 25% ROCE. Strategy is 50% domestic import replacement and 50% exports.
- Phase 2 in early R&D: Will add further chemistry including nitration and hydrogenation. R&D work has just started, with experienced hires being brought in for similar chemistry. The R&D team currently numbers 20-25 people and will expand continuously.
- Chlorine integration logic: After chlorotoluene and CPVC expansion, in-house chlorine consumption reaches 75%. The plan is to reach 85% before considering other value chains. The five-year strategy is 100% focus on derivatives with no further caustic soda capacity expansion.
Maulik Patel: "This is a first time in India, we have started focusing on this project in India. And we have already started a construction. Our project is almost 60% to 70% is completed. And we are going to commission by quarter for this financial year."
Geopolitical Tailwinds & Export Opportunity
- China plus one is real and flowing through: Big multinationals want to de-risk over-dependency on China, and new business is coming to India. Epigral benefits indirectly as domestic specialty chemical companies expand and Epigral supplies to them, with chlorotoluene cited as an example.
- US tariff advantage: The 25% US duty on Chinese manufacturing companies indirectly helps Indian manufacturers supply more to the US market.
- European chemical industry struggling: Mid-sized European specialty and chemical companies are suffering even after gas prices normalized. They are not thinking of expansion or capex, and volumes are shifting to India.
- Export share set to more than double: Company exports are expected to rise from approximately 4% in FY23 to 9-10% in FY24, driven by ECH. The current ECH split is 40% exports, 60% domestic, while CPVC will remain 100% domestic.
Maulik Patel: "So all those volume people are thinking now to manufacture in India. So Yes indirectly because of whatever the reasons Ukraine war or the Trump tax or we are getting indirectly advantage as a Indian as a chemical manufacturing."
Margins, Costs & the Energy Equation
- Q4 margin compression: EBITDA and PAT declined YoY on account of lower realizations, consumption of high-cost inventories, and higher depreciation and finance expenses from newly commissioned capacities.
- Blended margin range set: Management expects sustainable EBITDA margins of 28% plus/minus 2% (worst case 25%, best case 30%) for this year and coming years. The focus is on ROCE improvement as the portfolio shifts toward derivatives.
- Raw material pass-through mechanics: Raw material price fluctuations are normally pass-through, but timing depends on inventory levels and the specific product, taking one or two quarters depending on market conditions. CPVC and ECH pass-through is happening because demand is good.
- Coal cost absorption: Coal inventory is not very heavy and is normally absorbed in a couple of months. If coal prices fall, the advantage can be captured within one quarter.
- Energy strategy shifting to renewables: New energy requirements will be met through long-term contracts with renewable power suppliers rather than captive power plant investment, following the Europe/US/Japan model. The first phase of solar/renewable power tie-up is expected to commission from next month onwards after a Gujarat government policy hiccup.
- Power cost is a raw material for caustic soda: Power price changes must be passed on in caustic soda pricing. Derivatives where Epigral is expanding have very low power intensity compared to chloroalkali.
Milind Kotecha: "Our margins will remain in this range 28% plus minus two so worst case 25 and the best-case kind of a 30 but when we are entering into this derivative products our focus is on the ROCE which will improve like if compared to what we had, when we were just in chloralkali."
End-Market Demand & Sector Exposure
- Pharma segment picking up slowly: Pharma consumption was down in the last couple of quarters but has started recovering as normal conditions return. Chloromethane has high pharma weightage, while ECH has around 20% pharma intermediate exposure. Overall company pharma exposure is not a substantial share of total revenue.
- Pharma sector growth thesis: The API and intermediate sector is poised for growth over the next four to five years due to China plus one and Europe plus one dynamics, which will help absorb products in India.
- Agro opportunity emerging: New agro molecules will come to India as toll manufacturing or custom manufacturing for global multinationals, presenting a large volume opportunity.
- Chloromethane and the US EPA ban: The US EPA is proposing some restrictions on chloromethanes, but management believes India is far from that deadline, with 2032 cited as a continuation timeline for current refrigerant gas. No impact is expected on Indian chloromethane industries.
- Portfolio diversification as a stability lever: Over the next three to four years, Epigral will cater to 15-20 different end-user segments, moving away from dependence on any single end-user or product. This is expected to bring consistency in top line, bottom line, margins, and ROCE because not all industries underperform in the same year.
Maulik Patel: "As a India we believe that in India I think the still I think we are far away from that deadline. And I don't think so till 2,000 I think in 2032 I think we are going to continue with the refrigerant gas what we have right now."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume growth | 15% to 20% volume growth | FY24 |
| Value growth | 20% plus revenue growth | FY24 |
| EBITDA margin | Sustainable at 28% plus/minus 2% (range 25-30%) | FY24 and coming years |
| Derivative revenue share | Reach 50% of total revenue (from 38% in Q4 FY23) | By end of current financial year |
| In-house chlorine consumption | Reach 75% (from 65% currently) | When CPVC resin and chlorotoluene plants are commissioned |
| In-house chlorine consumption | Reach 85% | In two to three years |
| Chlorotoluene Phase 1 | Commissioning; targeting more than INR300 crores turnover, minimum 25% ROCE | Q4 FY23 |
| CPVC capacity expansion | Increase from 30,000 TPA to approximately 45,000 TPA | Volume contribution in FY25 |
| Revenue ambition | INR5,000 crores | By FY27 |
| Export share | Rise to 9-10% of company revenue (from ~4% in FY23) | FY24 |
| ECH utilization | Increase quarter-on-quarter from 40% | From Q1 FY24 onward |
| Solar/renewable power | First phase commissioning | From next month onward (post-Q4 FY23) |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue from operations | ₹562 cr, +13% YoY |
| FY23 revenue from operations | ₹2,188 cr, +41% YoY |
| FY23 PAT | ₹353 cr, +40% YoY |
| EBITDA margin | ~28%, company as a whole |
| Sustainable EBITDA margin guidance | 28% ±2%, worst case 25%, best case 30% |
| Volume growth | +15% YoY and +13% QoQ |
| FY24 volume growth expectation | 15% to 20% |
| FY24 value growth expectation | ~20%+ |
| Derivative and specialty chemical segment revenue contribution | 38% of revenue, vs 19% in Q4 FY22 |
| Derivative revenue target by end of FY24 | 50% of total revenue |
| Caustic soda ECU realization | ~₹38,000 |
| Caustic soda capacity utilization | ~78% on increased capacity of 4 lakh tons per annum |
| ECH realization | ~₹1,20,000 to ₹1,25,000 |
| ECH capacity utilization | ~40% |
| CPVC realization | ~₹1,50,000 to ₹1,60,000 |
| CPVC capacity utilization | ~90% |
| Hydrogen peroxide capacity utilization | ~98% to 100% |
| Hydrogen peroxide realization | ~₹27,000 |
| Chloromethane realization | ~₹40,000 to ₹45,000 |
| Chloromethane price change | ~-10% QoQ |
| Chlorine consumption in-house | 65%, target 85% in 2–3 years |
| Chlorine realization | ~-₹2,000 |
| Exports as percentage of total revenue | ~4% in FY23, expected 9–10% in FY24 |
| ECH export vs domestic split | 40% exports, 60% domestic at current situation |
| FY23 capex spent | ₹416 cr, vs ₹456 cr in FY22 |
| Net debt | ₹877 cr, decreased by ₹112 cr vs FY22 |
| Net debt-to-EBITDA | 1.3x, improved from 1.9x in FY22 |
| Net debt equity | 0.08x, vs 1.3x in FY22 |
| Return on capital employed (FY23) | 32%, vs 29% in FY22 |
| Return on equity (FY23) | 40%, vs 36% in FY22 |
| Proposed final dividend | ₹2.5 per equity share, 25% on face value of ₹10 |
| Coal price change | +30% YoY, -15% QoQ |
| Power generation cost change | -14% QoQ |
| Chlorotoluene Phase 1 revenue target | >₹300 cr turnover |
| Chlorotoluene Phase 1 ROCE target | ≥25% |
| Long-term revenue target | ₹5,000 cr by FY27 |